TransMedics Group, Inc. TMDX Proceeds from issuance of common stock relating to employee stock plans

Proceeds from issuance of common stock relating to employee stock plans at other companies

Edwards LifesciencesEW

$68.9M+38.1%

Other financials

Income statement

See full

Revenue$173.9M+21.2%

Gross profit$101.2M+14.7%

Operating income$13.3M-51.5%

Net income$7.3M-71.5%

EPS (diluted)$0.20-71.4%

Balance sheet

See full

Cash & equivalents$461.7M+48.9%

Total debt$409.9M+505%

Total equity$494.0M+85.5%

Total assets$1.4B+71.3%

Cash flow

See full

Operating cash flow$24.5M+959%

CapEx$36.7M+35.6%

Free cash flow-$12.1M+59.4%

Valuation

See full

Market cap$2.55B+50.6%

Enterprise value$2.5B+66.0%

P/E14.8×-19.8×

P/S4×+0.5×

Profitability

See full

Gross margin59.1%-0.4pp

Operating margin14.9%+4.1pp

Net margin27%+17.0pp

FCF margin23.8%—

Returns & leverage

See full

Return on equity45.2%+22.2pp

Debt / equity0.8×+0.6×

Current ratio6.7×-2.4×

Where this comes from

Reported directly by TransMedics Group, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockPlans.

The official record: TransMedics Group, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about TransMedics Group, Inc.'s proceeds from issuance of common stock relating to employee stock plans.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is TransMedics Group, Inc.'s proceeds from issuance of common stock relating to employee stock plans?: TransMedics Group, Inc. (TMDX) reported proceeds from issuance of common stock relating to employee stock plans of $1.69M in Q1 2026.
How has TransMedics Group, Inc.'s proceeds from issuance of common stock relating to employee stock plans changed year-over-year?: TransMedics Group, Inc.'s proceeds from issuance of common stock relating to employee stock plans increased by 31.3% year-over-year, from $1.29M to $1.69M.